James Bonucchi, DO
Endocrinology, Diabetes & Metabolism · Springfield, MONPI 1225054109
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,321 of the $128,500 with a category attached, or 80.4%. 43 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 28.8% of the total. Reporting peaked in 2019 at $60,468 and has fallen 74.2% since, to $15,596 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 686 payments — averaging $187.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$37K
- AstraZeneca$28K
- Lilly USA, LLC$21K
- Abbott$19K
- Boehringer Ingelheim$18K
- Novo Nordisk$840
- plus $4K from 37 others
What the payments were for
- Consulting fees$10,6068%
- Speaking & faculty fees$103,32180%
- Travel & lodging$4,1933%
- Food & beverage$10,3418%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$37,770
- FARXIGA$27,400
- SOLIQUA 100/33$24,492
- FREESTYLE LIBRE 3$17,017
- TOUJEO$14,999
- FreeStyle Libre$121
- Omnipod$112
How this compares
$128,500 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 208 | $215,725 |
| FarxigaDapagliflozin Propanediol | 207 | $177,442 |
| OzempicSemaglutide | 129 | $167,034 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 113 | $131,174 |
| Somatuline DepotLanreotide Acetate | 12 | $112,904 |
| TrulicityDulaglutide | 85 | $108,851 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 131 | $108,447 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 30 | $74,964 |
| Tresiba Flextouch U-200Insulin Degludec | 66 | $64,261 |
| MounjaroTirzepatide | 40 | $43,847 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $29,731 |
| ProliaDenosumab | 16 | $28,088 |
| Novolog FlexpenInsulin Aspart | 101 | $27,713 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $24,714 |
| TradjentaLinagliptin | 16 | $22,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $17,839 | $238,227224 claims |
| AstraZenecaFarxiga | $28,327 | $177,442207 claims |
| Novo NordiskOzempic, Novolog | $840 | $171,711146 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $21,487 | $152,698125 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37,042 | $131,174113 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $20 | $112,90412 claims |
| AmgenProlia | $784 | $28,08816 claims |
| MerckJanuvia | $43 | $22,26836 claims |
| AbbVieSynthroid | $56 | $13,985164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Springfield
- Ralph DudaSpringfield$644K
- Jonben SvobodaSpringfield$142K
- Ana Rivas MejiaSpringfield$5K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Christopher CaseJefferson City$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.